Akari Therapeutics opened higher at $7.49, compared with its previous close of $7.45. In the last trading session, the stock traded between $6.70 and $7.69. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Akari Therapeutics is now worth
$ 20.27
Resulting in a loss of
$ 79.73 (79.73%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 3 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.68 (-9.13%)
Day High
$7.69
Day Low
$6.70
Day Open
$7.49
Prev Close
$7.45
Volume
13,916
1W Return
-23.50%
1M Return
-21.26%
3M Return
-11.68%
6M Return
-15.38%
1Y Return
1,044.55%
Fundamentals
Market Cap ($ Mn)
8
PE Ratio
-
PB Ratio
1.03
PEG Ratio
-
ROE
-71.72%
ROCE
-54.29%
EPS (TTM)
$0.00
Investment Returns
1 Week
-23.50%
1 Month
-21.26%
3 Months
-11.68%
6 Months
-15.38%
9 Months
2,656.51%
Financials
Quarterly
All values in $ Mn
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Mar 26
0.0
Jun 26
Updates
11Nov
Akari Therapeutics features new CBO in investor segment
Vatnak Vat-Ho joins as Chief Business Officer. Segment highlights PH1 payload differentiation. Lead candidate AKTX-101 targets Trop2 receptor. First-In-Human trial targeted for mid-2027.
Yesterday
15Oct
Akari Therapeutics CEO outlines PH1 payload strategy for AKTX-101
Akari Therapeutics CEO Abizer Gaslightwala released a CEO Corner segment outlining the company's differentiated ADC payload strategy centred on the novel PH1 spliceosome-modulating payload. AKTX-101, targeting the Trop2 receptor, is advancing through IND-enabling toxicology and safety studies, large-scale GMP manufacturing, and Phase 1 planning, with a goal of initiating clinical development in mid-2027. Emerging clinical data presented at major medical conferences indicates sequential ADC treatment using the same payload class does not provide benefit after treatment relapse, underpinning Akari's unmet-need thesis. Recent industry transactions, including Novartis's agreement to acquire Myricx Bio and Genentech's collaboration with DualityBio, are cited as evidence of Big Pharma interest in novel ADC payload technologies. Akari is also developing AKTX-102, targeting CEACAM5, and is in discussions with potential strategic partners around licensing the PH1 payload platform.
28 days ago
13Oct
Akari Therapeutics appoints Vatnak Vat-Ho as Chief Business Officer
Appointed Vatnak Vat-Ho as Chief Business Officer. Brings over 20 years of oncology and biopharma experience. Led transactions totaling more than $25 billion in aggregate value. Previously closed ADC payload collaborations with Exelixis and BioNTech.
